News Releases

Avenge Bio to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NATICK, Mass. and QUINCY, Mass., Oct. 24, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced their poster presentation at the Society of Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) on November 1-5, 2023, in San Diego, California.

In September 2023, Avenge Bio received FDA Fast Tack designation for AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2) and is delivered intraperitoneally (IP) to patients. Avenge is currently enrolling patients in a First-in-Human, Phase 1/2, multicenter clinical trial (NCT05538624) designed to evaluate the safety and efficacy of AVB-001. The Company has advanced through multiple dose levels in a dose escalation cohort and expects to initiate a Phase 2 dose expansion trial in 1H 2024.

Abstract #: 1045
Poster Title: Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
Presenting Author: Guillaume Carmona, PhD
Location: Exhibit Halls A and B1
Date: Friday, November 3, 2023
Time: 9:00 AM-7:00 PM PDT

The poster will present how a single administration of either AVB-001 or AVB-002, engineered to produce native human IL-2 or native human IL-12 respectively, demonstrated complete responses as monotherapy and provided sustained eradication in various mouse tumor models. In addition, the poster will also present the commonalities and differences between AVB-001 and AVB-002 in modulating the innate and adaptive anti-tumor immune response. The poster will be available on the Presentations and Publications section of following the conference.

About LOCOcyte™ Platform 
Our LOCOcyteTM allogeneic cell-based immunotherapy platform enables potent localized modulation of the immune system which also precipitates a systemic immune response, allowing us to treat previously intractable cancers. The technology leverages three unique advantages:

(1)    Potent immune effector molecules are generated by synthetically engineering allogeneic cells creating a ready-to-use therapy,

(2)    Therapy is localized in proximity to the primary tumor site and generates innate and adaptive immune response, and

(3)    The immunomodulator trains the patient's immune system generating a robust immune response that seeks and eradicates distal metastasis without systemic toxicity.

About Avenge Bio
Avenge Bio, Inc. ("Avenge") is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor. This initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge was founded in 2019 base upon technology developed in the laboratory of Omid Veiseh, Ph.D. and has an exclusive license from Rice University for this technology. To learn more about Avenge visit: and follow us on LinkedIn , X, or Instagram.

SOURCE Avenge Bio, Inc.

For further information: MEDIA CONTACT: Angela Lam, Avenge Bio, Inc., Email:; Investor Contact: Doug Carlson, Avenge Bio, Inc., Email: